Targeted therapies in myeloid leukemia

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Targeted therapies, like all trans retinoic acid (ATRA) for APL and imatinib for CML, have transformed hematological malignancy treatment.
• Numerous molecular targets exist for other hematological malignancies, with several novel drugs in clinical trials.

Purpose of the Study:

• To review individual molecular abnormalities in myelodysplastic syndromes (MDS) and myeloid leukemias that serve as targets for small molecule therapies.
• To discuss fusion proteins (e.g., BCR-ABL), tyrosine kinase receptors (e.g., FLT3), and signaling pathways (e.g., RAS) as therapeutic targets.
• To examine targets related to the dysregulation of cell proliferation and apoptosis in MDS progression to acute myeloid leukemia (AML), including epigenetic modifications like p15(INK4B) silencing.

Main Methods:

• Literature review focusing on molecular targets in MDS and myeloid leukemias.
• Analysis of genetic abnormalities, including translocations, gene mutations, and epigenetic alterations.
• Discussion of small molecule inhibitors and their therapeutic potential.

Main Results:

• Identification of key molecular targets such as BCR-ABL, FLT3, and RAS in myeloid malignancies.
• Highlighting the role of altered cell proliferation and apoptosis in disease progression.
• Emphasis on the potential of targeting epigenetic silencing, exemplified by p15(INK4B).

Conclusions:

• Small molecule therapies targeting specific molecular abnormalities hold significant promise for treating MDS and myeloid leukemias.
• Understanding the molecular landscape of these diseases is crucial for developing effective targeted treatments.
• Further research into novel targets and drug development is warranted to improve patient outcomes.